#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Dementia Retinoblastoma Severe myoclonic epilepsy of infancy Neurotrophic keratopathy Round cell liposarcoma Immunodeficiency common variable Factor VIII deficiency Congenital leptin deficiency Facioscapulohumeral muscular dystrophy Ataxia telangiectasia PIK3CA related overgrowth spectrum Toxic epidermal necrolysis Anal cancer recurrent Systemic lupus erythematosus Progressive supranuclear palsy More trials…

    Learn about Rare Diseases

    Pelizaeus-Merzbacher disease – Treatment Factor VIII deficiency – Trials in Disease Hereditary hypophosphataemic rickets – Trials in Disease Bronchopulmonary dysplasia – Treatment Alternating hemiplegia of childhood Gaucher’s disease type III – Life with Disease Loeys-Dietz syndrome – Diagnostics Erdheim-Chester disease – Treatment Cystic fibrosis lung Mitochondrial myopathy – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Betamethasone Valerate AAV9-CTNT-COBAG3 GSK5764227 Estradiol Valerate Trientine Dihydrochloride LUXDEGALUTAMIDE Alx148 Cefotaxime Birtamimab Lumateperone Cdr132L Sodium Amy109 OMTX705 Aon-D21 Vgl101 Milademetan Cinnarizine Tipiracil ZIGAKIBART Faricimab More therapies…

    Learn about Your Condition

    Incontinence Colon cancer stage IV Prinzmetal angina Pneumonia Acute myeloid leukaemia Duchenne muscular dystrophy Acute leukaemia Atrial fibrillation Head and neck cancer stage IV Nervous system disorder Pulmonary alveolar haemorrhage Desmoid tumour Petit mal epilepsy Hyperhidrosis Osteosarcoma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Naxitamab Added to Standard Induction Therapy for Children and Teenagers with Newly Diagnosed High-Risk Neuroblastoma

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neuroblastoma
    Investigated Drugs:
    • Naxitamab
    Spain

  • Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Zongertinib
    • Carboplatin
    • Cisplatin
    France Germany Spain

  • Durvalumab and Chemotherapy in Adults With Muscle-Invasive Bladder Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Durvalumab
    France Italy The Netherlands Spain

  • BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

    Recruiting

    2 1
    Investigated Diseases:
    • Renal disorder
    Investigated Drugs:
    • [4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
    Belgium Croatia Denmark Estonia France Germany +10

  • Bisoprolol in Patients After Myocardial Infarction with Preserved Ejection Fraction During Cardiac Rehabilitation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Heart failure with preserved ejection fraction
    • Acute myocardial infarction
    Investigated Drugs:
    • Bisoprolol
    Belgium

  • Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +14
Previous Page
1 … 12 13 14 15 16 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!